Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has a price-to-earnings ratio of 218.52x that is above its average ratio. Additionally, the 36-month beta value for AUPH is 1.21. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for AUPH is 122.12M and currently, short sellers hold a 9.42% ratio of that float. The average trading volume of AUPH on March 21, 2025 was 1.41M shares.
AUPH) stock’s latest price update
The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has surged by 1.38 when compared to previous closing price of 8.32, but the company has seen a 3.37% gain in its stock price over the last five trading sessions. 247wallst.com reported 2025-03-11 that Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
AUPH’s Market Performance
AUPH’s stock has risen by 3.37% in the past week, with a monthly rise of 7.73% and a quarterly drop of -11.68%. The volatility ratio for the week is 2.40% while the volatility levels for the last 30 days are 4.71% for Aurinia Pharmaceuticals Inc The simple moving average for the past 20 days is 3.35% for AUPH’s stock, with a 16.07% simple moving average for the past 200 days.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at 5.06% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.95% of loss for the given period.
Volatility was left at 4.71%, however, over the last 30 days, the volatility rate increased by 2.40%, as shares surge +5.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.24% lower at present.
During the last 5 trading sessions, AUPH rose by +2.94%, which changed the moving average for the period of 200-days by +56.72% in comparison to the 20-day moving average, which settled at $8.16. In addition, Aurinia Pharmaceuticals Inc saw -6.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Keenan Greg, who sale 8,305 shares at the price of $8.23 back on Mar 07 ’25. After this action, Keenan Greg now owns 153,484 shares of Aurinia Pharmaceuticals Inc, valued at $68,350 using the latest closing price.
Greenleaf Peter, the Chief Executive Officer of Aurinia Pharmaceuticals Inc, sale 195,593 shares at $8.00 during a trade that took place back on Mar 03 ’25, which means that Greenleaf Peter is holding 1,953,892 shares at $1,564,744 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.88 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at 0.02. The total capital return value is set at -0.0. Equity return is now at value 1.52, with 1.05 for asset returns.
Based on Aurinia Pharmaceuticals Inc (AUPH), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at 0.56. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -0.28.
Currently, EBITDA for the company is 31.73 million with net debt to EBITDA at -0.14. When we switch over and look at the enterprise to sales, we see a ratio of 4.88. The receivables turnover for the company is 6.43for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.57.
Conclusion
In conclusion, Aurinia Pharmaceuticals Inc (AUPH) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
